Silo pharma announces pricing of $2 million public offering

Sarasota, fl, may 15, 2025 (globe newswire) -- silo pharma, inc. (nasdaq: silo) (“silo” or the “company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced the pricing of a public offering of 3,333,338 shares of common stock (or pre-funded warrants in lieu thereof), together with series a-1 warrants (“series a-1 warrants”) to purchase up to 3,333,338 shares of common stock and series a-2 warrants (“series a-2 warrants”) to purchase up to 3,333,338 shares of common stock at a combined public offering price of $0.60 per share (or pre-funded warrant in lieu thereof) and associated series a-1 warrant and series a-2 warrant. the series a-1 warrants will have an exercise price of $0.60 per share, are exercisable upon issuance and will expire five years thereafter. the series a-2 warrants will have an exercise price of $0.60 per share, are exercisable upon issuance and will expire eighteen months thereafter. the closing of the offering is expected to occur on or about may 16, 2025, subject to the satisfaction of customary closing conditions.
SILO Ratings Summary
SILO Quant Ranking